Solid Biosciences (SLDB) Prepaid Assets (2017 - 2026)
Solid Biosciences (SLDB) posted Prepaid Assets of $15.5 million for Q1 2026, down 5.58% sequentially from $16.4 million in Q4 2025, and up 138.33% YoY from $6.5 million in Q1 2025.
Analysis
Solid Biosciences (SLDB) Prepaid Assets (2017 - 2026) Analysis & Trends
Solid Biosciences has reported Prepaid Assets for 10 years, with the latest figure at $15.5 million in Q1 2026.
- Quarterly Prepaid Assets rose 138.33% year-over-year to $15.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.5 million (up 138.33% YoY) and the FY2025 annual result came in at $16.4 million, up 95.47% from the prior year.
- Prepaid Assets slipped to $15.5 million in Q1 2026 per SLDB's latest filing, from $16.4 million in the prior quarter.
- Over five years, Prepaid Assets peaked at $18.5 million in Q1 2022 and troughed at $5.1 million in Q1 2023.
- A 5-year average of $8.9 million and a median of $7.3 million in 2024 frame the typical range for Prepaid Assets.
- The sharpest annual moves came in 2022 and 2023: Prepaid Assets soared 236.06% in 2022, then slumped 72.52% in 2023.
- Over 5 years, Prepaid Assets stood at $5.9 million in 2022, then gained by 3.01% to $6.1 million in 2023, then soared by 37.55% to $8.4 million in 2024, then surged by 95.47% to $16.4 million in 2025, then fell by 5.58% to $15.5 million in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $15.5 million, $16.4 million, and $8.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Solid Biosciences | 1.48 Bn | 1.48 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 16.79 Mn |
| Mar 31, 2026 | 15.47 Mn |
| Dec 31, 2025 | 16.38 Mn |
| Sep 30, 2025 | 8.71 Mn |
| Jun 30, 2025 | 10.53 Mn |
| Mar 31, 2025 | 6.49 Mn |
| Dec 31, 2024 | 8.38 Mn |
| Sep 30, 2024 | 8.38 Mn |
| Jun 30, 2024 | 7.34 Mn |
| Mar 31, 2024 | 8.13 Mn |
| Dec 31, 2023 | 6.09 Mn |
| Sep 30, 2023 | 5.46 Mn |
| Jun 30, 2023 | 7.28 Mn |
| Mar 31, 2023 | 5.10 Mn |
| Dec 31, 2022 | 5.92 Mn |
| Sep 30, 2022 | 5.12 Mn |
| Jun 30, 2022 | 7.32 Mn |
| Mar 31, 2022 | 18.54 Mn |
| Dec 31, 2021 | 14.72 Mn |
| Sep 30, 2021 | 8.37 Mn |